Genvax
生物技术
Ames，Iowa 1,555 位关注者
We accelerate breakthrough solutions to the animal health industry.
关于我们
Genvax is a startup animal vaccine company located in Ames, Iowa. We have a dynamic team of experienced scientists and entrepreneurs poised to develop next generation RNA + nanoparticle vaccines for animal health. This isn’t the first go-around for co-founders Joel Harris and Dr. Hank Harris, who successfully created, grew and sold Harrisvaccines to Merck Animal Health in 2015. Our Mission: Genvax Technologies accelerates breakthrough solutions to the animal health industry. We commercialize the tools for livestock producers and veterinarians that no one else can. Our Vision: We believe in rapidly responding to the world around us. We cultivate new ideas to develop novel solutions and create a long-lasting impact on animal health world-wide.
- 网站
-
https://www.genvax.com
Genvax的外部链接
- 所属行业
- 生物技术
- 规模
- 2-10 人
- 总部
- Ames，Iowa
- 类型
- 私人持股
- 创立
- 2021
地点
-
主要
获取路线
2503 S Loop Dr
STE 5446
US，Iowa，Ames，50010
Genvax员工
动态
-
Our co-founder and CEO, Joel Harris, was named 2025 Biotech Leader of the Year at the?Iowa Biotechnology Association (IowaBio) Biotech Showcase & Conference! This award?honors exceptional individuals who have shown leadership, consistently delivered innovative biotech solutions, and actively advocate for Iowa's biotechnology sector. Congratulations, Joel! #IBSC
-
-
Genvax转发了
Want to learn more about raising capital and working with strategic investors for biotech startups?? Join Ag Startup Engine’s Mikayla (Sullivan) Mooney and Joel Harris at the Iowa Biotechnology Association (IowaBio) Showcase and Conference on Wednesday, March 5th! Joel will share key insights from building Genvax and navigating the biotech funding landscape. ?? To learn more about the event visit:?https://lnkd.in/ges7Ri8w
-
-
?? Genvax Technologies is celebrating 4 years of innovation and progress! ?? From our early vision to where we stand today, it has been an incredible journey. None of this would be possible without our dedicated team, supportive investors, trusted partners, and the broader animal health community that believes in our mission. Over the past four years, we have: ? Built a world-class team dedicated to advancing self-amplifying RNA vaccines. ? Secured key funding to drive our technology forward. ? Pioneered solutions for animal health and future pandemic preparedness. Thank you to everyone who has supported us on this journey! Here's to the future of Genvax and the impact we continue to make. ?? #GenvaxTechnologies #4YearAnniversary #AnimalHealth #BiotechInnovation #ThankYou
-
-
Doubling down on Iowa! We are thrilled to announce the first close of our third Iowa investment fund. The fund also closed its first investment in Genvax, an animal health startup developing the next generation mRNA + nanoparticle animal vaccines. Thank you to our initial investors for supporting us in our mission to help build and scale innovative companies in Iowa!
-
?? Major Milestone for Self-Amplifying mRNA in Human Health ?? The European Commission just approved the first self-amplifying RNA (saRNA) vaccine for humans, marking a significant leap forward in vaccine technology. This decision, based on EMA’s recommendation, validates the power of saRNA and lipid nanoparticle (LNP) delivery systems—a field that continues to evolve at an incredible pace. At Genvax Technologies, we’ve been pioneering the use of saRNA + LNP for animal health, where speed, adaptability, and cost-efficiency are game-changers for protecting livestock and ensuring food security. This approval underscores the broader potential of the platform and reinforces the importance of regulatory pathways for next-gen RNA vaccines. As we push forward in animal health, we’re excited to see how these innovations will continue shaping both human and veterinary medicine. Congrats to CSL and Arcturus Therapeutics on this milestone! https://lnkd.in/dqinSB7F #SelfAmplifyingRNA #saRNA #mRNA #VaccineInnovation #AnimalHealth #HumanHealth #Biotech #GenvaxTechnologies
-
Genvax转发了
?? ????????'?? ?????? ???????? ?????????????????????? ???? ?????? ???????????????????? ???????????? ????????????????? ?? Closing off our production animal track for the afternoon, Aaron Schacht, CEO, BiomEdit moderated a discussion exploring of the current product landscape, with a focus on the most exciting new innovations, from diagnostics to mRNA technology, and discuss how they are poised to evolve over the next decade. Thank you to panelists Eve Hanks (MI:RNA Diagnostics), Adrian Grosu (Stonehaven Cozmix Group (SC Group) , Lucas Huntimer (Genvax) and Colin South (ArkeaBio?) for an exciting conversation. #AHNTI #AnimalHealth #10YearsOfAHNTI
-
-
What has led to disruptive innovation in livestock #animalhealth in the last 10 years? Vaccines! #AHNTI #10YearsOfAHNTI
-
-
Proactive measures are key in fighting H5N1. Experts stress innovation & preparedness to protect livestock & food security. ???? #HPAI #AnimalHealth #Biosecurity https://lnkd.in/gWkedfBp
-
We’re thrilled to welcome Dr. Lucas Huntimer as our Chief Scientific Officer! His deep expertise in animal vaccine R&D strengthens our mission to develop RNA vaccines for emerging threats like high-path avian influenza. This milestone is possible thanks to a strong coalition of investors and industry leaders—including United Animal Health, Johnsonville Holdings, Inc., Iowa Corn Growers, Iowa Farm Bureau’s Rural Vitality Funds, Next Level Ventures, and Ag Startup Engine—who share our vision for protecting animal health and securing the future of food production. We’re just getting started! ?????? ?? Read the press release here: https://shorturl.at/KE8iZ #Genvax #AnimalHealth #Vaccines #Innovation #RNA #FoodSecurity #AgTech
-